Primer pair and application thereof
By designing specific primer pairs, the problem of Lactobacillus fermentation mucinous detection in complex environments was solved, efficient and accurate identification in fecal samples was achieved, and the accuracy of diarrhea treatment and drug efficacy experiments was supported.
Patent Information
- Application Number
- CN202311472994.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2023-11-07
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to accurately detect the colonization of Lactobacillus fermented mucinous in complex environments, especially in the intestine, which affects its clinical application in the treatment of diarrhea and the accuracy of drug efficacy experiments.
Specific primer pairs were designed and screened. Through PCR and qPCR methods, L. fermented mucosa Lferm-1 can be easily and accurately identified in fecal samples, improving the sensitivity and accuracy of detection.
It realizes efficient and accurate detection in complex environments, solves the problems of colonization detection and strain identification, and provides a basis for treating diarrhea and adjusting treatment plans.
Smart Images

Figure CN118995697A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of microbial detection, and relates to a primer pair and an application thereof, and in particular to a specific primer pair for detecting fermenting mucus lactobacillus and an application thereof in preparing a preparation for detecting a subject's tolerance to several diarrheas, etc. Background Art
[0002] In recent years, research related to intestinal microbiota and human health has emerged in an endless stream, and has become a hot topic in microbial research. Probiotics are active beneficial microorganisms that colonize in the human and animal intestines and reproductive systems, and can produce definite health effects, thereby improving the host's microecological balance and playing a beneficial role. Colonization is a prerequisite for probiotics to function in the body, so understanding the colonization of probiotics in the body can assist in evaluating their effectiveness and help guide medication. qPCR technology can be used to determine the number of bacterial species in a sample.
[0003] At present, the common methods for detecting the colonization ability of strains are as follows: A. Fluorescence imaging: by feeding strains labeled with fluorescent proteins, the location and number of the target strain in the intestine are detected; B. Metagenomic sequencing: by metagenomic sequencing, the relative abundance of the target strain is detected; C. Live bacteria count: by using selective culture medium to count the live bacteria of the target strain; D. qPCR detection: using universal primers to quantitatively detect strains at the phylum / family / genus / species level. qPCR detects the colonization ability of strains, and generally uses universal primers to detect the strain content at the phylum / family / genus / species level. It is difficult to design specific primers, and in the context of complex bacterial flora, there are technical challenges in tracking individual strains, making it difficult to achieve accurate quantification of strains.
[0004] There have been no reports on the clinical application of intestinal probiotics (especially fermented mucus lactobacillus) to treat anti-tumor therapy-related diarrhea. If such probiotics can be prepared, it may reduce side effects during treatment, and the cost of culturing microorganisms is low. Of course, detecting whether there are such active bacteria in the intestinal flora of the subjects will also help evaluate the subjects' own ability to resist tumor therapy-related diarrhea or related symptoms, and help guide personalized treatment plans for tumor patients. Summary of the invention
[0005] The purpose of the present invention is to provide a specific primer for detecting Lactobacillus mucus fermenting Lferm-1 in complex environmental samples such as feces and application thereof.
[0006] In order to screen primers that can specifically amplify the target strain in feces, PCR was used to amplify normal mouse feces. After screening specific primers, it is necessary to detect the background amplification of the strain-specific primers in mouse feces. If the number of viable bacteria amplified by the background is greater than the animal dosage, the method is not sensitive enough and the primers need to be rescreened. Therefore, using the primers that have passed the rescreening, with feces and feces + different concentrations of plasmid DNA as templates, the sensitivity of the test method is finally determined.
[0007] The present invention aims to amplify mouse feces by screening specific genes, designing specific primers, screening specific primers that can specifically amplify the target strain in feces, and establishing a method for mixing mouse fecal DNA with plasmids of different concentrations to obtain primers that can specifically amplify the target strain in feces, thereby providing an efficient and accurate identification method for detecting fermented mucus Lactobacillus Lferm-1, thereby solving the problems of colonization detection and strain identification faced in animal efficacy experiments.
[0008] The specific primers provided by the present invention meet the requirements of no band in the negative control (no DNA template), single band in the positive control (single bacterial DNA), and no band in the fecal DNA sample, indicating that the primers can be used for the detection of the content of fermented mucus lactobacillus Lferm-1.
[0009] More specifically, in order to solve the problems existing in the prior art, the first aspect of the present invention provides a primer pair, which can amplify a genomic fragment with a sequence such as SEQ ID NO.15 or a sub-fragment thereof with a length greater than 50 nt.
[0010] Obviously, the sub-fragment of the genomic fragment shown in SEQ ID NO. 15 can still be used to detect the template of the fragment.
[0011] In some embodiments, in the primer pair, the sequences downstream of the primers that are complementary to the template are shown as SEQ ID NO.7 and SEQ ID NO.8, respectively.
[0012] When a primer has several unpaired bases (tails) or molecular markers (for example, fluorescent molecules) upstream, it does not affect the amplification effect of this primer pair, and at least the amplification product can be characterized by gel electrophoresis.
[0013] In some embodiments, in the primer pair, the primer sequences are shown as SEQ ID NO.7 and SEQ ID NO.8, respectively.
[0014] The second aspect of the present invention provides a primer combination, which is a combination of the primer pair described in the first aspect of the present invention and any one, any two, any three or four of the second primer pair, the third primer pair, the fourth primer pair and the fifth primer pair;
[0015] In the second primer pair, the sequences downstream of the primers complementary to the template are shown as SEQ ID NO.3 and SEQ ID NO.4 respectively;
[0016] In the third primer pair, the sequences downstream of the primers complementary to the template are shown as SEQ ID NO.5 and SEQ ID NO.6 respectively;
[0017] In the fourth primer pair, the sequences downstream of the primers complementary to the template are shown as SEQ ID NO.9 and SEQ ID NO.10 respectively; and
[0018] In the fifth primer pair, the sequences downstream of the primers that are complementary to the template are shown as SEQ ID NO.11 and SEQ ID NO.12 respectively.
[0019] Obviously, when two or more primers are used for parallel detection, the detection accuracy will be improved.
[0020] In some embodiments, in the second primer pair, the primer sequences are shown as SEQ ID NO.3 and SEQ ID NO.4 respectively;
[0021] In the third primer pair, the primer sequences are shown as SEQ ID NO.5 and SEQ ID NO.6 respectively;
[0022] In the fourth primer pair, the primer sequences are shown as SEQ ID NO.9 and SEQ ID NO.10 respectively; and
[0023] In the fifth primer pair, the primer sequences are shown as SEQ ID NO.11 and SEQ ID NO.12 respectively.
[0024] The third aspect of the present invention provides a kit, which contains the primer pair described in the first aspect of the present invention or the primer combination described in the second aspect of the present invention.
[0025] A fourth aspect of the present invention provides a method for detecting Lactobacillus mucilaginosus fermentation with a microbial deposit number of CCTCC NO: M2023352 for non-diagnostic purposes;
[0026] The method comprises: using the primer pair described in the first aspect of the present invention, the primer combination described in the second aspect of the present invention or the kit described in the third aspect of the present invention to detect the genome template in the sample to be tested.
[0027] One application scenario of the method for detecting fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 for non-diagnostic purposes is: in order to study the competitive advantage of Lferm-1 over other bacteria, the two are mixed and cultured, and then the absolute or relative content of Lferm-1 in the culture is detected, so as to know the competitive advantage of the two bacteria in the common ecological environment and understand the competition mechanism of the two bacteria.
[0028] In some embodiments, the microorganisms contained in the sample to be detected are determined by detecting the electrophoresis image of the amplified product by the PCR method; or
[0029] The microorganisms contained in the sample to be detected are determined by the qPCR method.
[0030] A fifth aspect of the present invention provides a use of a biomaterial in a medical-related operation, wherein the use is as follows U1, U2 or U3:
[0031] U1: Use of the genomic fragment as shown in SEQ ID NO. 15 or a sub-fragment thereof having a length greater than 50 nt, the primer pair as described in the first aspect of the present invention, the primer combination as described in the second aspect of the present invention or the kit as described in the third aspect of the present invention in the preparation of a preparation for evaluating a subject's ability or state to tolerate, resist, prevent or alleviate a disease or sub-health;
[0032] The subject is selected from humans, dogs and mice;
[0033] The ability or state of tolerating, resisting, preventing or alleviating disease or sub-health is selected from any one, any two, any three or four of the following four aspects:
[0034] The ability or state to tolerate, resist, prevent, or alleviate diarrhea;
[0035] Improve the antioxidant capacity or status in the intestine;
[0036] Reduce intestinal damage caused by chemotherapy drugs;
[0037] The ability or state to tolerate, resist, prevent or alleviate disease or sub-health by reducing the expression of IL-6 and / or TNF-α genes;
[0038] U2: Use of the primer pair described in the first aspect of the present invention, the primer combination described in the second aspect of the present invention, or the kit described in the third aspect of the present invention in preparing a preparation for evaluating the therapeutic effect of probiotics, wherein the active bacteria in the probiotics are fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352; and
[0039] U3: Use of the primer pair described in the first aspect of the present invention, the primer combination described in the second aspect of the present invention or the kit described in the third aspect of the present invention in the preparation of a preparation for formulating or adjusting a treatment plan for tumor patients.
[0040] In some embodiments, in U1, the diarrhea is chemotherapeutic drug-induced diarrhea; or
[0041] The diarrhea is caused by any one, any two, any three or four of Salmonella paratyphi B, Staphylococcus aureus, Yersinia enterocolitica and Clostridium difficile; or
[0042] In U1, the method for implementing the use is: qualitatively or quantitatively detecting the fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 in the intestinal contents or feces of the subject; or
[0043] In U2, the method for implementing the use is: qualitatively or quantitatively detecting the fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 in the intestinal contents or feces of the subject; or
[0044] In U3, the method for realizing the use is: qualitatively or quantitatively detecting the fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 in the intestinal contents or feces of the subject.
[0045] In some embodiments, in U1, the chemotherapy drug is selected from 5-fluorouracil, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin-paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, irinotecan and its derivatives.
[0046] Obviously, when the subject (for example, human) contains fermented mucus lactobacillus (Lferm-1) with a microbial deposit number of CCTCCNO: M2023352 in the intestine, it can better resist oxidation in the intestine, is less likely to have diarrhea or has milder diarrhea symptoms, and the inflammation manifested as increased expression of IL-6 and / or TNF-α genes will be milder. The primer pair described in the first aspect of the present invention, the primer combination described in the second aspect of the present invention, or the kit described in the third aspect of the present invention can be used to detect whether Lferm-1 is contained in the intestinal contents or feces, and then evaluate the relative strength of the subject's ability to tolerate, resist, prevent or alleviate the diseases or sub-health corresponding to the above indicators. For the genomic fragment shown in SEQ ID NO.15, it can be used as the basis for designing PCR primers, and its sub-fragments with a length greater than 50nt can also be amplified. When designing nucleic acid hybridization-based detection technologies such as gene chip probes, its full length or sub-fragments can be used. Therefore, use U1 is a use based on the actual contribution of the present invention.
[0047] Lferm-1 itself comes from the feces of human volunteers, does not cause hemolysis of red blood cells, is resistant to gastric acid, and has at least the aforementioned use of improving health conditions. When Lferm-1 is used as a probiotic to regulate human health conditions, the actual or approximate action state of Lferm-1 can be evaluated by detecting the absolute or relative content of Lferm-1 in the intestinal contents or feces after the administration of Lferm-1 at least by using the primer pair described in the first aspect, the primer combination described in the second aspect of the present invention, or the kit described in the third aspect of the present invention. Therefore, use U2 is a use based on the actual contribution of the present invention.
[0048] Lferm-1 can reduce diarrhea and intestinal damage caused by chemotherapy drugs (such as 5-fluorouracil). Therefore, for patients with Lferm-1 in the intestine, it is possible to consider moderately reducing the types or doses of anticancer drugs, while for patients without Lferm-1 in the intestine, the types or doses of anticancer drugs can be relatively increased. By detecting Lferm-1 in intestinal contents or feces using the primer pair described in the first aspect of the present invention, the primer combination described in the second aspect of the present invention, or the kit described in the third aspect of the present invention, reference data can be provided for formulating or adjusting treatment plans for cancer patients. Therefore, use U3 is a use based on the actual contribution of the present invention.
[0049] The key technical points of the present invention are: 1. Screening and obtaining a specific primer for fermenting mucus lactobacillus; 2. The specific primer can have a higher accuracy in complex environmental samples; 3. Screening and obtaining specific primers in complex environmental samples. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1A frontal photograph of the colony morphology of the fermented mucus Lactobacillus Lferm-1 of the present invention is shown.
[0051] Figure 2 The results of in vitro antioxidant tests of fermented Lactobacillus mucilaginosus Lferm-1 and Lactobacillus rhamnosus are shown.
[0052] Figure 3 The results of the antibacterial test of fermented Lactobacillus mucilaginosus Lferm-1 against various pathogenic bacteria are shown.
[0053] Figure 4 The results of in vitro cell inflammation inhibition test of each experimental group are shown, A shows the effect on IL-6 expression, and B shows the effect on TNF-α expression.
[0054] Figure 5 The therapeutic effects of each experimental group on mice with diarrhea caused by 5-fluorouracil are shown. A shows the diarrhea score curves of each group from day 1 to day 9; B shows the total diarrhea score graph of each group.
[0055] Figure 6 The effects of each experimental group on the pathological damage of the colon in mice with 5-fluorouracil-induced diarrhea were shown. A shows the HE staining results of each group; B shows the total pathological score of each group.
[0056] Figure 7 The effect of each experimental group on the expression of TNF-α gene in the colon of mice with 5-fluorouracil-induced diarrhea is shown.
[0057] Figure 8 Specific primer detection results are shown (n=2).
[0058] Fig. 9 Specific primer detection results are shown (n=10).
[0059] Fig.10 PCR test results are shown.
[0060] Fig.11 The results of qPCR detection of Lactobacillus mucofermentans Lferm-1 in feces are shown. DETAILED DESCRIPTION
[0061] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be further described in detail below with reference to the accompanying drawings.
[0062] Preparation of triple-mixed liquid culture medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3), and 5 g of agar powder, dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, and store in a cool and dry place.
[0063] Preparation of three-mix solid culture medium (BHI+MRS+modified GAM): Add 5 g agar powder to the three-mix liquid culture medium, and the other steps are the same.
[0064] Preparation of the second mixed culture medium (BHI+MRS): Weigh 19.25 g of BHI broth powder, 27.0 g of MRS broth powder, and 0.5 g of cysteine hydrochloride monohydrate (Emeishan Longteng Biotechnology Co., Ltd.), dissolve in 1 L of distilled water, deoxygenate and package, sterilize at 121°C for 15 min, and store in a cool and dry place.
[0065] Preparation of YCFA liquid culture medium: weigh 10.0 g of casein peptone, 2.5 g of yeast extract, 0.45 mL of MgSO4·7H2O (10% mother liquor), 0.45 mL of CaCl2 (10% mother liquor), 10 mL of TE141, 0.45 g of K2HPO4, 0.45 g of KH2PO4, 0.90 g of NaCl, and 3.2 mL of VFA-mix, dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, store in a cool and dry place for later use.
[0066] Preparation of TE141: Weigh 1.50 g of Nitrilotriacetic acid and add it to 200 mL of pure water, add an appropriate amount of NaOH until the solution becomes clear, then add 800 mL of water, adjust the pH value to 5.5 with 50% HCl, then weigh 3.00 g of MgSO4·7H2O, 0.50 g of MnSO4·H2O, 1.00 g of NaCl, 0.10 g of FeSO4·7H2O, 0.18 g of CoSO4·7H2O, 0.10 g of CaCl2·2H2O, 0.18 g of ZnSO4·7H2O, 0.006 g of CuSO4·5H2O, 0.02 g of KAl(SO4)2·12H2O, 0.01 g of H3BO3, 0.01 g of Na2MoO4·2H2O, and 0.01 g of NiCl2·6H2O. 0.03 g, 0.03 mL (10 mg / mL stock solution) of Na2SeO3·5H2O, and 0.03 mL (10 mg / mL stock solution) of Na2WO4·2H2O were added to the above test solution. Stir continuously during the addition process to keep the solution clear for later use.
[0067] Preparation of VFA-mix: Measure 90 mL of acetic acid, 30 mL of propionic acid, 10 mL of n-valeric acid, 10 mL of isobutyric acid, and 10 mL of butyric acid, mix well for later use, and adjust to neutrality with 5 M NaOH before use.
[0068] Example 1: Isolation and identification of new strains
[0069] Collect fresh fecal samples from healthy human volunteers, add appropriate amount of anaerobic PBS to resuspend, shake, and make sure the sample is fully resuspended. Under N2 protection, filter twice through gauze, and dispense the filtrate into 50mL centrifuge tubes. Centrifuge at 10000rpm for 20min and discard the supernatant. Add appropriate amount of anaerobic PBS to resuspend the bacteria in the centrifugal precipitate, then add an equal volume of 50% anaerobic glycerol to mix thoroughly, and dispense into 2mL screw cap tubes, 0.5mL each. After dispensing, bag and vacuum-pack in a -80℃ refrigerator for later use.
[0070] When separating, take out one frozen sample tube, resuspend 0.5 mL of the thawed sample in 4.5 mL of anaerobic PBS, vortex and shake for 5 min, transfer to the anaerobic glove box, take 0.5 mL of the bacterial suspension in 4.5 mL of anaerobic PBS, shake and mix, and dilute tenfold to 10 -6Dilution, take appropriate bacterial solution gradient and mix with YCFA medium, then divide into 384-well plates and culture for one week. Pick the bacterial solution of the growing wells for transfer. After 48 hours of culture, one copy is detected by MALDI-TOF-MS, and the isolated strains are preliminarily classified. After determining that the well contains only bacteria with one genetic background (monoclonal strain), the other copy is transferred to a 96-well plate again according to the mass spectrometry results. After 48 hours of culture, one plate is amplified for 16S rDNA sequence and sent to the Chengdu branch of Beijing Qingke Biotechnology Co., Ltd. for sequencing. The other plate is temporarily stored by adding 50% glycerol at a ratio of 1:1 and temporarily named strain a for use after the PCR results are confirmed.
[0071] The PCR results of 16S rDNA were sequenced and analyzed, and the sequence was compared with the NCBI nt library. The results showed that the sequence similarity with a strain of Limosilactobacillus fermentum was the highest (100%). Therefore, strain a was preliminarily identified as Limosilactobacillus fermentum (formerly known as Lactobacillus fermentum). The Latin word Limosilactobacillus fermentum corresponds to fermented mucus lactobacillus in Chinese, also known as fermented mucus lactobacillus and fermented lactobacillus. Strain a was officially named fermented mucus lactobacillus Lferm-1. Its colony morphology is white opaque round colonies with a convex middle and a smooth and moist surface. The front photo is shown in Figure 1 .
[0072] Example 2: Whole genome analysis and identification of new strains
[0073] Strain a was inoculated into 5 mL of anaerobic three-mixed liquid medium at a 2% inoculum and cultured until the late logarithmic growth stage. The whole genome DNA of strain a was extracted and whole genome sequencing was performed using the Illumina high-throughput sequencing platform NovaSeq 6000. After conventional assembly and annotation, the protein sequence was entered into the Virulence Factor Databases (VFDB) for virulence factor analysis. The results showed that the bacteria did not have virulence factors. The average nucleotide similarity (Average Nucleotide Identity, ANI) was used to analyze the novelty of the strain. By searching in Genbank, 126 published Limosilactobacillus fermentum whole genomes were found. By comparing with fastANI (v1.33), it was found that the two strains most similar to the present whole genome were GCA_003465085.1 (ANI=99.32%) and GCA_024385625.1 (ANI=99.29%), so strain a can be considered as a new strain, classified as fermentative mucus Lactobacillus, and named fermentative mucus Lactobacillus Lferm-1 strain, abbreviated as Lferm-1 or Lferm-1 strain.
[0074] The strain Lferm-1 was deposited in the China Center for Type Culture Collection (CCTCC) on March 17, 2023. The center’s address is Wuhan University, Wuhan, China. The strain’s accession number is: CCTCCNO: M2023352. The classification name is Limosilactobacillus fermentum, which corresponds to fermented mucus Lactobacillus in Chinese. The culture name is Limosilactobacillus fermentum Lferm-1. The identified survival date is: March 24, 2023.
[0075] Example 3: Hemolysis test of fermented Lactobacillus mucilaginosus Lferm-1
[0076] The preserved fermented mucus lactobacillus Lferm-1 was inoculated into 5mL of anaerobic three-mixed liquid medium at a 2% inoculation rate, and anaerobically cultured at 37°C until the late logarithmic growth period to obtain an activated strain. The bacterial suspension after resuspending 2mL of 2% fresh rabbit red blood cell suspension (Beijing Borsi Technology Co., Ltd.) and 2mL of 0.9% sterile saline (Shandong Qidu Pharmaceutical Co., Ltd.) was tested by liquid contact method, with an equal volume of sterile water as a positive control (hemoglobin is released after red blood cells absorb water and burst), and an equal volume of 0.9% sterile saline as a negative control. Three parallels were set for each group, and each sample was photographed after standing for 24 hours. The results showed that the fermented mucus lactobacillus Lferm-1 bacterial suspension had no hemolysis, so there was no risk of hemolysis when applied to the human body.
[0077] Example 4: Gastric acid resistance of fermented Lactobacillus mucilaginosus
[0078] Inoculate the fermented mucus Lactobacillus Lferm-1 into 5 mL of anaerobic three-mixed liquid medium at a 2% inoculum and culture until the late logarithmic growth period. Take 1 mL of the cultured bacterial liquid for centrifugation (8000 rpm, 5 min), discard the supernatant and resuspend the bacteria with 1 mL of pH 3.0 artificial gastric juice (pepsin: Shanghai Yuanye Biotechnology Co., Ltd., S10028), and incubate anaerobically at 37°C for 3 hours. Resuspend the bacteria in 1 mL of anaerobic and resazurin-free PBS as a control. Take appropriate amounts of the incubated bacterial suspension and dilute it 10 times with anaerobic and resazurin-free PBS. Take 10 -4 ~10 -6 50 μL of the gradient bacterial suspension was mixed with 0.5% three-mix solid medium, and cultured anaerobically at 37°C until a single colony grew and then counted. The survival rate of the strain resistant to gastric juice = the number of viable bacteria in the gastric juice incubation group / the number of viable bacteria in the PBS incubation group × 100%. Three parallels were set for each group, and the test results were expressed as Mean ± SEM.
[0079] The experimental results showed that the number of viable bacteria of Lactobacillus mucilaginosus Lferm-1 incubated in anaerobic and resazurin-free PBS for 3 h was (3.40±0.17)×10 8 CFU / mL; after treatment with pH 3.0 artificial gastric juice, the number of viable bacteria was (3.42±0.52)×10 8 CFU / mL, and the tolerance rate to pH 3.0 artificial gastric juice was 100.49±15.23%. Lactobacillus mucis Lferm-1 has a strong tolerance to pH 3.0 gastric juice. Therefore, Lferm-1 can survive normally in human gastric juice, which meets the basic requirement of gastrointestinal probiotics to resist gastric juice.
[0080] Example 5: Antioxidant Experiment of Fermented Lactobacillus mucilaginosus
[0081] The preserved fermented mucus Lactobacillus Lferm-1 was activated and inoculated into 5 mL of anaerobic BF839 medium at a 2% inoculum size. Lactobacillus rhamnosus GG (Lactobacillus rhamnosus, CICC6141, China Industrial Microbiological Culture Collection Center) was used as a positive control. All strains were anaerobically cultured in anaerobic BF839 medium at 37°C for 24 h.
[0082] Sample processing: Take 0.5mL of culture solution and centrifuge at 12000rpm for 20min, discard the supernatant, and resuspend with 0.5mL of the extract (pre-cooled) in the total antioxidant capacity detection kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC1315); transfer to a sterile screw-cap tube containing beads (Sigma-Aldrich Company, G4649-1KG), oscillate and break the wall once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), centrifuge at 12000rpm and 4℃ for 10min, and take the supernatant and place it on ice for testing.
[0083] A BCA protein concentration determination kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., PC0020) was used to draw a standard curve and detect the protein content in the sample according to the instructions of the kit.
[0084] The total antioxidant capacity detection kit of strains (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC1315) was used to determine the antioxidant capacity of the sample according to the instructions of the kit and the standard curve. The total antioxidant capacity per unit sample was calculated according to the protein concentration, in μmol / mg prot. The total antioxidant capacity results of the control bacteria and the test bacteria can be found in Figure 2 .
[0085] Depend on Figure 2 It can be seen that the total antioxidant capacity of strain Lferm-1 reached 0.345±0.056μmol / mg prot, which was comparable to that of the positive control strain Lactobacillus rhamnosus GG, indicating that Lferm-1 had antioxidant capacity in vitro.
[0086] Example 6: Antibacterial ability test of fermented Lactobacillus mucilaginosus against pathogenic bacteria
[0087] In this example, four common pathogenic bacteria that cause diarrhea were selected for antibacterial ability testing. The source information of the pathogenic strains is as follows: Salmonella paratyphi B (CMCC (B) 50094), from the China Food and Drug Administration. Staphylococcus aureus (CMCC (B) 26003), from the China Food and Drug Administration. Yersinia enterocolitica CMCC (B) 52204, from the China Food and Drug Administration. Clostridium difficile (CICC 22951), from the China Industrial Microbiological Culture Collection Center.
[0088] Obtaining fermentation broth of Lactobacillus mucilaginosus: After being activated, Lactobacillus mucilaginosus Lferm-1 is inoculated at an inoculum rate of 2% into an anaerobic three-mixed liquid culture medium and cultured anaerobically at 37° C. for 48 hours to obtain fermentation broth.
[0089] Preparation and coating of pathogens: Salmonella paratyphi B, Yersinia enterocolitica and Staphylococcus aureus are aerobic bacteria. After activation with TSB broth medium, they were diluted 50 times in TSB broth medium to reach the appropriate concentration, and 0.2 mL of the diluted bacterial solution was coated on TSA solid medium. Clostridium difficile is an anaerobic bacterium. After anaerobic activation and transfer, it was diluted 50 times in anaerobic three-mixed liquid medium (BHI+MRS+modified GAM), and 0.2 mL of the diluted bacterial solution was coated on anaerobic GAM solid medium (added with 5% horse serum, Beijing Solebow Technology Co., Ltd., S9050).
[0090] Co-cultivation of Lactobacillus mucilaginosus and pathogens: Place 3 sterilized Oxford cups on each coated pathogen plate, add 0.2 mL of Lactobacillus mucilaginosus fermentation liquid into the Oxford cups, place in a culture box (anaerobic pathogens plus anaerobic gas production bag), place the plate upright for 24 hours, and measure the size of the inhibition zone with a vernier caliper.
[0091] The statistical results are as follows Figure 3 As shown: Fermented Lactobacillus mucilaginosus has antibacterial ability against Salmonella paratyphi B, Yersinia enterocolitica, Staphylococcus aureus and Clostridium difficile.
[0092] Example 7: In vitro cell inflammation inhibition test of fermented Lactobacillus mucilaginosus
[0093] THP-1 cell polarization: RPMI-1640 (Thermo Fisher, C11875500BT) medium containing 10 v / v% FBS and a final concentration of 100 ng / mL PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich Company, P1585) was used at 1×10 5 THP-1 cells were seeded in a 96-well plate at a seeding density of 10 cells / well and placed in a 5% CO2 incubator at 37°C for 24 h to polarize them into mature macrophages.
[0094] Strain culture: Inoculate 200 μL of the fermented Lactobacillus mucilaginosus Lferm-1 culture medium from the bacterial storage into 5 mL of the second mixed culture medium, and culture anaerobically in a 37°C electric constant temperature incubator for 24 hours. After transferring once, culture anaerobically for 8 hours. Take 1 mL of the culture medium and centrifuge at 5000 rpm / min for 15 minutes. Dilute to 2×10 with RPMI-1640 culture medium containing 10% (v / v) FBS. 6 CFU / mL is reserved.
[0095] Effect of fermented lactobacillus Lferm-1 on the expression of TNF-α and IL-6 in THP-1 cells: After the mature THP-1 cells were cultured, the normal control group was replaced with RPMI-1640 medium containing 10% FBS; the model group, positive control group and Lferm-1 test group were replaced with RPMI-1640 medium containing 10% FBS, a final concentration of 100ng / mL LPS (Sigma-Aldrich Company, L3024) and 20ng / mL IFN-γ (PeproTech, AF-300-02) to model inflammatory macrophages. Each group was placed in a 5% CO2 incubator and cultured at 37°C for 24h. The culture medium was aspirated, and 100 μL of RPMI-1640 culture medium containing 10% (v / v) FBS was added to the normal control group and the model group, respectively; 100 μL of RPMI-1640 culture medium containing 10% (v / v) FBS and dexamethasone (purchased from Sigma-Aldrich Company, D4902-25) with a final concentration of 25 μg / mL was added to the positive control group; 100 μL of the fermented Lactobacillus Lferm-1 culture medium prepared in advance was added to the Lferm-1 test group. After being cultured in a 5% CO2 incubator at 37°C for 24 h, 80 μL of cell culture medium was aspirated from each group, and the cells were centrifuged at 4°C, 5000 rpm / min for 15 min. The supernatant was collected and the TNF-α content was detected using a Human TNF-α ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H0109c), and the IL-6 content was detected using a Human IL-6 ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H6156).
[0096] Experimental results: Figure 4 As shown, the expression of IL-6 and TNF-α in the model control group was significantly higher than that in the normal control group (P<0.01); the positive control dexamethasone group could significantly inhibit the expression of proinflammatory factors IL-6 and TNF-α in THP-1 cells (P<0.01); the fermented Lactobacillus mucus Lferm-1 group could also significantly reduce the expression of proinflammatory factors IL-6 and TNF-α compared with the model group (P<0.05), indicating that the strain has a certain anti-inflammatory effect in vitro.
[0097] Example 8: Therapeutic effect of fermented Lactobacillus mucilaginosus on 5-FU-induced diarrhea in mice
[0098] Preparation of freeze-dried protective agent: Solution A: 8g sucrose, 8g trehalose, 44g purified water, sterilized at 115℃ for 30min; Solution B: 2g sodium glutamate, 2g arginine hydrochloride, 16g purified water, sterilized at 115℃ for 30min; Solution C: 4g sodium vitamin C, 16g purified water.
[0099] Filter and sterilize for later use. When using, mix in a volume ratio of A:B:C = 6:2:2.
[0100] Preparation of bacterial powder: The preserved fermentation mucus lactobacillus Lferm-1 was inoculated into the bacterial powder preparation fermentation medium at a 10% inoculation rate, and anaerobically cultured at 37°C and 90rpm to obtain a first-level seed solution (OD 600 Then, the inoculation amount of 1.5% was transferred to the bacterial powder to prepare the fermentation medium, and the secondary seed solution (OD 600 The secondary seeds were inoculated at 1.5% with a peristaltic pump into a fermentation tank containing bacterial powder and fermentation medium, and the fermentation parameters (temperature 37°C, pH=5.1, speed 100rpm, pressure control 0.06MPa) were set to start fermentation. 600 Value ≥1.5 or OD 600 When the value increases by ≤0.1, the fermentation is stopped and the bacterial liquid is collected. The bacterial liquid is divided into centrifugal buckets, centrifuged and the supernatant is discarded. Freeze-drying protective agent is added at a weight ratio of 1:1 to 1:2 to emulsify the bacterial mud. The emulsified bacterial suspension is placed on the plate layer of a freeze dryer cooled to -40°C and freeze-dried. After the freeze-drying process is completed, the bacterial cake is taken out and crushed to obtain the bacterial powder. Before animal administration, the fermented mucus Lactobacillus Lferm-1 is prepared with physiological saline to a concentration of 5×10 9 CFU / mL of bacterial suspension.
[0101] Experimental animals: 20 SPF-grade male Balb / c mice, weighing 18-22 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and kept in an SPF-grade animal room.
[0102] Experimental design: 5-FU (5-fluorouracil, purchased from Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / tube, 0.25g / 10mL) solution was used to induce chemotherapy-related diarrhea model in mice. The mice were randomly divided into 4 groups according to their initial body weight, namely normal control group, model control group, positive control loperamide group and fermented Lactobacillus mucinus Lferm-1 group, with 5 mice in each group.
[0103] The total experimental period was 9 days, recorded as D1-D9. A single 5-FU model was created on D3. Except for the normal control group, which was intraperitoneally injected with normal saline, all other groups were treated with a single 5-FU intraperitoneal injection. The modeling dose was based on body weight (350 mg / kg).
[0104] All groups were given drugs by gavage. The normal control group and the model control group were gavaged with lyophilized protective agent for 5 consecutive days (D1-D5). The positive control group was gavaged with loperamide (purchased from Xi'an Janssen Pharmaceutical Co., Ltd.) for 9 consecutive days (D1-D9, 20 mg / kg) according to body weight. The Lferm-1 group was gavaged for 5 consecutive days (D1-D5) with 1×10 9 CFU fermented Lactobacillus mucilaginosus. After the end of D5 administration, the subjects were observed for 4 consecutive days. The specific experimental groups and administration schemes are shown in Table 1.
[0105] Table 1. Trial groups and dosing regimen
[0106]
[0107] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day
[0108] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the daily diarrhea scores.
[0109] Test results: Figure 5 As shown in the figure, compared with the model control group, the Lferm-1 group had a significant improvement effect on 5-FU-induced diarrhea, and the effect was not much different from that of the positive control loperamide ( Figure 5 A); both loperamide and fermented Lactobacillus mucilaginosus Lferm-1 could significantly reduce the total score of diarrhea (P<0.05) ( Figure 5 B).
[0110] Example 9: Fermented Lactobacillus mucilaginosus Lferm-1 improves colon pathological damage in mice with 5-FU-induced diarrhea
[0111] The method for constructing the animal model is the same as in Example 8. All animals were dissected at D10, and the mid-segment colon was collected and fixed in 4% paraformaldehyde for 24 hours. The fixed colon tissue was dehydrated, transparent, waxed and embedded in sequence. The embedded colon tissue wax block was sliced to a thickness of 5 μm, followed by spreading and baking, and the dried slices were subjected to conventional HE staining. The pathological changes were observed under an optical microscope, and the pathological scores were performed according to Table 2, and the total pathological score (the sum of the scores of each index) was calculated.
[0112] Table 2. Colon histopathology scoring indicators and descriptions
[0113]
[0114] Test results: Figure 6 As shown in A, a is the normal control group, b is the model control group, c is the loperamide group, and d is the Lferm-1 group. The colon structure of the normal control group was intact, and the mucosal layer, submucosal layer, muscular layer and serosa layer were clearly visible; in the model control group, necrosis and dissolution of intestinal glands, decreased goblet cells, lymphocyte infiltration, loose connective tissue in the submucosal layer, and dilation of blood vessels were observed in the colon propria; in the loperamide group, the colon structure was relatively intact, no obvious necrosis of mucosal epithelial cells was observed, the number of goblet cells increased significantly, and only a small amount of lymphocyte infiltration was observed in the propria; in the Lferm-1 group, a small amount of mucosal epithelial cell necrosis was observed in the colon tissue, accompanied by a small amount of lymphocyte infiltration; a small amount of intestinal glands were dilated; the number of goblet cells was slightly reduced; mild edema was observed in the submucosal layer, accompanied by a small amount of lymphocyte infiltration.
[0115] Depend on Figure 6 B shows that after 5-FU induction, the mouse colon showed obvious damage. The total pathological score of the model control group was significantly higher than that of the normal control group (P<0.01). After administration of fermented mucus lactobacillus Lferm-1, the total pathological score was consistent with that of the loperamide group, which significantly reduced the total pathological score of the colon (P<0.05) and improved the degree of colon damage.
[0116] It can be seen that fermented Lactobacillus mucilaginosus Lferm-1 can significantly improve the pathological damage of mouse colon caused by 5-FU.
[0117] Example 10: Effect of fermented Lactobacillus mucilaginosus Lferm-1 on the mRNA transcription level of TNF-α in the colon of mice with 5-FU-induced diarrhea
[0118] The method for constructing the animal model was the same as in Example 8. After the experiment, all animals were dissected on D10, and the mid-colon was collected and stored in a -80°C refrigerator. According to the instructions of the kit (Thermo Fisher Scientific, Cat. No. 15596026), the total RNA of the colon tissue of each group of mice was extracted and reverse transcribed into cDNA, which was stored at -20°C for later use. The relative transcription level of the TNF-α gene mRNA in the colon of each group of mice was detected by qRT-PCR (primer sequences are shown in F1, R1 below). Reaction procedure: 95°C for 3min, 95°C for 20s, 60°C for 45s, 72°C for 20s, for a total of 39 cycles. 2 -ΔΔCT The data were analyzed by SPSS 24.0 statistical software.
[0119] F1 (SEQ ID NO.1): 5'-CTGTAGCCCACGTCGTAGC-3'
[0120] R1 (SEQ ID NO.2): 5'-TTGAGATCCATGCCGTTG-3'
[0121] Test results see Figure 7 : Compared with the normal control group, the relative transcription level of TNF-α mRNA in the model control group was extremely significantly increased (P<0.01). The relative transcription level of TNF-α mRNA did not decrease significantly after loperamide treatment, while the administration of Lferm-1 could significantly reduce the relative transcription level of TNF-α mRNA (P<0.01).
[0122] It can be seen that the fermented Lactobacillus mucius Lferm-1 of the present invention can improve diarrhea symptoms in many aspects and has a significant therapeutic effect on chemotherapy-related diarrhea.
[0123] Example 11: Specific primer design and synthesis
[0124] According to the results of the whole genome analysis of Lactobacillus fermentans Lferm-1, we searched for specific genomic fragments based on this strain, designed specific primers using Primer Premier 5, and commissioned Beijing Qingke Biotechnology Co., Ltd. to synthesize the primers. The primer information is shown in Table 3. The specific fragment screening method is as follows: 1) First, the original genome data is subjected to routine quality control, assembly, and annotation to obtain the gene sequence as the input file. 2) The sequences in the input file are compared with the NCBI nt library by default to query whether these sequences match the data in the database. If a certain sequence has no match in the database, it means that the fragment has strong specificity, as the result.
[0125] Table 3. Primer information
[0126]
[0127] Example 12: Single bacteria culture, single bacteria whole genome DNA extraction and feces genomic DNA extraction
[0128] 1) Strain culture: used for whole genome DNA extraction.
[0129] The preserved fermented mucus lactobacillus Lferm-1 was activated in a three-mixed liquid culture medium at a 2% (v / v) inoculation rate and cultured anaerobically at 37° C. to the late logarithmic growth stage.
[0130] 2) A bacterial culture DNA extraction kit (Shanghai Sangon Biotech Co., Ltd., B518255) was used to extract whole genome DNA from the bacterial culture according to the instructions of the kit for specific primer screening.
[0131] 3) A stool DNA extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP328-02) was used according to the instructions of the kit to extract stool genomic DNA for specific primer screening.
[0132] Example 13: Screening of specific primers for detecting Lactobacillus mucilaginosus Lferm-1
[0133] In order to screen primers that can specifically amplify the target strain in feces, PCR was used to amplify normal mouse feces. Due to individual differences in mice and differences in intestinal flora composition, 10 normal mouse feces samples were selected to specifically screen the designed primers to enhance reliability. In order to reduce the workload, 2 fecal DNA samples were randomly selected for initial screening of each primer. After no obvious background amplification, 10 fecal DNA samples were used to rescreen each primer and select the primer with the strongest specificity.
[0134] 1) Sample source: extraction of single bacterial whole genome DNA and extraction of 2 or 10 fecal genome DNA in Example 12.
[0135] 2) PCR test:
[0136] ① For primer information, please see Table 3; for primer sequence information, please see Table 4:
[0137] Table 4. Primer sequence information
[0138]
[0139]
[0140] ② PCR amplification system (total system is 25 μl): 1.1×T3 Super PCR Mix (Beijing Qingke Xinye Biotechnology Co., Ltd., TSE030) 22 μl, 10 μmol / L upstream and downstream primers 1 μl each, and template DNA 1 μl, were added into corresponding PCR tubes respectively.
[0141] ③PCR reaction program: Place the constructed reaction system on the PCR instrument and set the corresponding amplification program as follows: 98℃ for 2 min; 98℃ for 10 s, 56℃ for 10 s, 72℃ for 50 s, for a total of 39 cycles; 72℃ for 2 min; store at 4℃.
[0142] 3) Agarose gel electrophoresis results:
[0143] like Figures 8-9 In each gel photo, the primer number is marked on the photo. In the sample number, M: Maker; NC: negative control (normal saline); PC: positive control (genomic DNA of single bacteria Lferm-1); 1 to 10 (feces sample number): total DNA extracted from feces. Figure 8 Primers A, B, C, and E satisfy the conditions of no bands in NC, single band in PC, and no bands in fecal DNA samples 1 and 6. The results are verified successfully and used for rescreening. Fig. 9 Primer C met the conditions of no band in NC, single band in PC, and no band in fecal DNA samples 1 to 10, which was successfully verified and used for subsequent experiments.
[0144] Example 14: PCR identification and plasmid construction
[0145] 1) Sequence sequencing identification: The PCR product amplified from the target single bacterial DNA sample corresponding to the primer C that passed the re-screening in Example 13 was entrusted to Beijing Qingke Biotechnology Co., Ltd. for sequencing, and the PCR sequencing result was compared with the whole genome sequencing sequence to confirm that the results were consistent, and then plasmid construction was performed, indicating that the amplification result was in line with expectations.
[0146] 2) Plasmid construction:
[0147] ① According to the primer sequence and the target fragment sequence (the fragment sequence obtained by amplification), Beijing Qingke Biotechnology Co., Ltd. was commissioned to synthesize the plasmid. The target vector was pMD-19T, Amp + Resistance, the amplified fragment was inserted into the target vector to obtain a recombinant plasmid containing the target DNA fragment, and 4 μg of plasmid sample was obtained for each recombinant plasmid.
[0148] ② Take 4 μg (=4000 ng) of the synthetic plasmid sample, centrifuge at low speed before use, add 40 μl of sterile double distilled water to prepare a 100 ng / μl plasmid solution (see Table 5 for plasmid information), and calculate the copy number. The copy number calculation method is as follows:
[0149]
[0150] Table 5. Plasmid and initial screening primer information
[0151]
[0152] 1) PCR identification:
[0153] ① Sample source: Extraction of whole genome DNA of a single bacterium and synthesis of plasmid in Example 12.
[0154] ②PCR detection: Primer information, PCR amplification system, and PCR reaction procedure are the same as those in step 2 of Example 13).
[0155] ③Agarose gel electrophoresis results:
[0156] like Fig.10As shown in the figure, in each gel photo, the primer number is marked on the photo, and in the sample number, M: Maker; NC: negative control; PC: positive control (synthetic plasmid); 1: single bacterial DNA. The PC (synthetic plasmid) and the sample amplification band length are consistent, and NC (negative control) has no band, and the plasmid synthesis is successfully verified. 16S sequencing was performed on each amplified sample, and the sequencing results were compared to the target strain and the sample was not contaminated.
[0157] Example 15: qPCR detection of specific primers for Lactobacillus mucilaginosus Lferm-1 in mouse feces
[0158] After screening out specific primers, it is necessary to detect the background amplification of the strain-specific primers in mouse feces. If the number of viable bacteria amplified by the background is greater than the animal dosage, the method sensitivity is insufficient and the primers need to be rescreened. Therefore, using the primers (primer C) that passed the rescreening in Example 13, with feces DNA (negative control), feces + DNA of different concentrations of plasmids (experimental group) and each single bacterial plasmid (positive control group) as templates, the sensitivity of the detection method was finally determined.
[0159] 1) Sample processing:
[0160] ① Sample source: fecal genomic DNA extraction in Example 12.
[0161] ②Sample grouping and mixing: Add different concentrations of plasmids to fecal DNA to verify the accuracy of the qPCR method. Each DNA / plasmid sample was grouped and combined according to Table 6 for qPCR detection.
[0162] Table 6. Methods for establishing experimental groups
[0163]
[0164]
[0165] 2) qPCR detection:
[0166] ①Plasmid and primer information is shown in Table 5.
[0167] ②qPCR amplification system (total system is 10μl): SsoFast Eva Green (Bio-Rad Biomedical Products (Shanghai) Co., Ltd., 1725201) 5μl, ddH2O 2.25μl, BSA (Baori Medical Biotechnology (Beijing) Co., Ltd., 2320) 0.25μl, 10μmol / L upstream and downstream primers 0.25μl each, template DNA 2μl, were added into the corresponding qPCR tubes respectively.
[0168] ③qPCR reaction procedure: Place the constructed reaction system on a qPCR instrument and set the corresponding amplification program as follows: 95°C for 2 min; 95°C for 15 s, 56°C for 15 s, 72°C for 10 s, for a total of 45 cycles; 72°C for 5 min; Melt Curve from 65°C to 95°C with an increment of 0.5°C,
[0169] ④Standard curve establishment: Take the plasmid sample and perform a 10-fold dilution according to DNA:ddH2O = 5:45 to dilute the DNA to 10 10 、10 9 、10 8 、10 7 、10 6 、10 5 、10 4 、10 3 、10 2 copies / μl, place on ice for later use; load the samples for detection according to the qPCR amplification system and qPCR reaction procedure.
[0170] ⑤Sample detection: Take the samples in Table 6 and load them for detection according to the qPCR amplification system and qPCR reaction procedure.
[0171] Results: The results are as Fig.11 shown in A: R 2 > 0.99, 80% < E < 120%, the standard curve is successfully established. The results are as Fig.11 shown in B: The background value of Lactobacillus mucosae Lferm - 1 is relatively low, at 10 1 ~10 3 copies / μl. The bacterial content amplified from the DNA of the experimental group (feces + different concentrations of plasmid) is basically the same as that amplified from the DNA of the positive control group (different concentrations of plasmid), indicating that the method is successfully established, and this primer can be used to detect the content of Lactobacillus mucosae Lferm - 1 in fecal samples.
[0172] It can be seen that the genomic fragment corresponding to primer C is a specific fragment of Lactobacillus mucosae Lferm - 1 and can be used to distinguish and identify Lactobacillus mucosae.
[0173] The sequence of the genomic fragment corresponding to primer C is as follows (SEQ ID NO.15):
[0174] GCTGGAAGTTCTCTAATATCAAGGACGGGGTCTTCGCCACTCGTTTCCACGTTAACGACGCCGACGGGAACCTGGCTCACCTACCGGATGAAATTGACCCGACCGAGGCCTGCATGCTTTCCGACATGATCCCAACTGGCCTCCACGCTTCCGAAATGGCGGGTGTGA CCTTTGGGGATGCCGTCGCCGTGATTGGGATCGGCCCGGTTGGCTTGATGGCCCTGCGCGGGGCGGTGCTCCACGGGGCTGGCCGCGTCTTTGCGGTTCACGGGAAAAGACGGTCGAAGTGGCTAAAAAGTACGGCGCAACCGACATCATTGACTACCACAACG
[0175] It is known from common technical knowledge that the present invention can be implemented by other embodiments that do not deviate from its spirit or essential features. Therefore, the above disclosed embodiments are only illustrative in all respects and are not exclusive. All changes within the scope of the present invention or within the scope equivalent to the present invention are included in the present invention.
Claims
1. A primer pair capable of amplifying a genomic fragment having a sequence as shown in SEQ ID NO.15 or a sub-fragment thereof having a length greater than 50 nt.
2. The primer pair according to claim 1, characterized in that In the primer pair, the sequences downstream of the primers that are complementary to the template are shown as SEQ ID NO.7 and SEQ ID NO.8 respectively; or In the primer pair, the primer sequences are shown as SEQ ID NO.7 and SEQ ID NO.8 respectively.
3. A primer combination, which is a combination of the primer pair according to claim 1 or 2 and any one, any two, any three or four of the second primer pair, the third primer pair, the fourth primer pair and the fifth primer pair; In the second primer pair, the sequences downstream of the primers complementary to the template are shown as SEQ ID NO.3 and SEQ ID NO.4 respectively; In the third primer pair, the sequences downstream of the primers complementary to the template are shown as SEQ ID NO.5 and SEQ ID NO.6 respectively; In the fourth primer pair, the sequences downstream of the primers complementary to the template are shown as SEQ ID NO.9 and SEQ ID NO.10 respectively; and In the fifth primer pair, the sequences downstream of the primers that are complementary to the template are shown as SEQ ID NO.11 and SEQ ID NO.12 respectively.
4. The primer combination according to claim 3, characterized in that In the second primer pair, the primer sequences are shown as SEQ ID NO.3 and SEQ ID NO.4 respectively; In the third primer pair, the primer sequences are shown as SEQ ID NO.5 and SEQ ID NO.6 respectively; In the fourth primer pair, the primer sequences are shown as SEQ ID NO.9 and SEQ ID NO.10 respectively; and In the fifth primer pair, the primer sequences are shown as SEQ ID NO.11 and SEQ ID NO.12 respectively.
5. A kit comprising the primer pair according to claim 1 or 2 or the primer combination according to claim 3 or 4.
6. A method for detecting Lactobacillus mucilaginosus fermentation with a microbial deposit number of CCTCC NO: M2023352 for non-diagnostic purposes; The method comprises: using the primer pair described in claim 1 or 2, the primer combination described in claim 3 or 4, or the kit described in claim 5 to detect the genome template in the sample to be tested.
7. The method according to claim 6, characterized in that By using the PCR method, detecting the electrophoresis image of the amplified product, determining the microorganisms contained in the sample to be detected; or The microorganisms contained in the sample to be detected are determined by the qPCR method.
8. Use of a biomaterial in a medical-related operation, wherein the use is as follows U1, U2 or U3: U1: Use of the genomic fragment as shown in SEQ ID NO. 15 or a sub-fragment thereof having a length greater than 50 nt, the primer pair as described in claim 1 or 2, the primer combination as described in claim 3 or 4, or the kit as described in claim 5 in the preparation of a preparation for evaluating a subject's ability or state to tolerate, resist, prevent or alleviate a disease or sub-health; The subject is selected from humans, dogs and mice; The ability or state of tolerating, resisting, preventing or alleviating disease or sub-health is selected from any one, any two, any three or four of the following four aspects: The ability or state to tolerate, resist, prevent, or alleviate diarrhea; Improve the antioxidant capacity or status in the intestine; Reduce intestinal damage caused by chemotherapy drugs; The ability or state to tolerate, resist, prevent or alleviate disease or sub-health by reducing the expression of IL-6 and / or TNF-α genes; U2: Use of the primer pair according to claim 1 or 2, the primer combination according to claim 3 or 4, or the kit according to claim 5 in preparing a preparation for evaluating the therapeutic effect of probiotics, wherein the active bacteria in the probiotics are fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352; and U3: Use of the primer pair described in claim 1 or 2, the primer combination described in claim 3 or 4, or the kit described in claim 5 in the preparation of a preparation for formulating or adjusting a treatment plan for a tumor patient.
9. The use according to claim 8, characterized in that In U1, the diarrhea is chemotherapeutic drug-induced diarrhea; or The diarrhea is caused by any one, any two, any three or four of Salmonella paratyphi B, Staphylococcus aureus, Yersinia enterocolitica and Clostridium difficile; or In U1, the method for implementing the use is: qualitatively or quantitatively detecting the fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 in the intestinal contents or feces of the subject; or In U2, the method for implementing the use is: qualitatively or quantitatively detecting the fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 in the intestinal contents or feces of the subject; or In U3, the method for realizing the use is: qualitatively or quantitatively detecting the fermented mucus lactobacillus with a microbial preservation number of CCTCC NO: M2023352 in the intestinal contents or feces of the subject.
10. The use according to claim 8 or 9, characterized in that: In U1, the chemotherapy drug is selected from 5-fluorouracil, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, albumin-paclitaxel, cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, irinotecan and their derivatives.
